Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists.
Autoimmune disease
COVID-19
Children
Inflammation
Opinion poll
Pediatric rheumatology
SARS-CoV-2
Treatment
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
26
11
2020
accepted:
25
02
2021
pubmed:
9
3
2021
medline:
20
4
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
Data on therapy of COVID-19 in immunocompetent and immunosuppressed children are scarce. We aimed to explore management strategies of pediatric rheumatologists. All subscribers to international Pediatric Rheumatology Bulletin Board were invited to take part in an online survey on therapeutic approaches to COVID-19 in healthy children and children with autoimmune/inflammatory diseases (AID). Off-label therapies would be considered by 90.3% of the 93 participating respondents. In stable patients with COVID-19 on oxygen supply (stage I), use of remdesivir (48.3%), azithromycin (26.6%), oral corticosteroids (25.4%) and/or hydroxychloroquine (21.9%) would be recommended. In case of early signs of "cytokine storm" (stage II) or in critically ill patients (stage III) (a) anakinra (79.5% stage II; 83.6% stage III) or tocilizumab (58.0% and 87.0%, respectively); (b) corticosteroids (oral 67.2% stage II, intravenously 81.7% stage III); (c) intravenous immunoglobulins (both stages 56.5%); or (d) remdesivir (both stages 46.7%) were considered. In AID, > 94.2% of the respondents would not support a preventive adaptation of the immunomodulating therapy. In case of mild COVID-19, more than 50% of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroquine (94.2%), anakinra (79.2%) or canakinumab (72.5%), or tocilizumab (69.8%). Long-term corticosteroids would be reduced by 26.9% (< = 2 mg/kg/d) and 50.0% (> 2 mg/kg/day), respectively, with only 5.8% of respondents voting to discontinue the therapy. Conversely, more than 75% of respondents would refrain from administering cyclophosphamide and anti-CD20-antibodies. As evidence on management of pediatric COVID-19 is incomplete, continuous and critical expert opinion and knowledge exchange is helpful.
Identifiants
pubmed: 33683393
doi: 10.1007/s00296-021-04824-4
pii: 10.1007/s00296-021-04824-4
pmc: PMC7938886
doi:
Substances chimiques
Antirheumatic Agents
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-920Références
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM (2020) COVID-19: Immunology and treatment options. Clin Immunol 215:108448. https://doi.org/10.1016/j.clim.2020.108448
doi: 10.1016/j.clim.2020.108448
pubmed: 32353634
pmcid: 7185015
Pain CE, Felsenstein S, Cleary G et al (2020) Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30137-5
doi: 10.1016/S2665-9913(20)30137-5
pubmed: 32427161
pmcid: 7228732
Felsenstein S, Hedrich CM (2020) SARS-CoV-2 infections in children and young people. Clin Immunol 220:108588. https://doi.org/10.1016/j.clim.2020.108588
doi: 10.1016/j.clim.2020.108588
pubmed: 32905851
pmcid: 7474910
Hedrich CM (2020) COVID-19 – Considerations for the paediatric rheumatologist. Clin Immunol 214:108420. https://doi.org/10.1016/j.clim.2020.108420
doi: 10.1016/j.clim.2020.108420
pubmed: 32283324
pmcid: 7151358
Swann OV, Holden KA, Turtle L et al (2020) Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: Prospective multicentre observational cohort study. BMJ 370:m3249. https://doi.org/10.1136/bmj.m3249
doi: 10.1136/bmj.m3249
pubmed: 32960186
pmcid: 7488201
Knight SR, Ho A, Pius R et al (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. BMJ 370:m3339. https://doi.org/10.1136/bmj.m3339
doi: 10.1136/bmj.m3339
pubmed: 32907855
pmcid: 7116472
Docherty AB, Harrison EM, Green CA et al (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369:m1985. https://doi.org/10.1136/bmj.m1985
doi: 10.1136/bmj.m1985
pubmed: 32444460
pmcid: 7243036
Ding Y, Yan H, Guo W (2020) Clinical Characteristics of Children With COVID-19: A Meta-Analysis. Front Pediatr 8:431. https://doi.org/10.3389/fped.2020.00431
doi: 10.3389/fped.2020.00431
pubmed: 32719759
pmcid: 7350605
Castagnoli R, Votto M, Licari A et al (2020) Severe Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review. JAMA Pediatr 174:882–889. https://doi.org/10.1001/jamapediatrics.2020.1467
doi: 10.1001/jamapediatrics.2020.1467
pubmed: 32320004
Pouletty M, Borocco C, Ouldali N et al (2020) Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort. Ann Rheum Dis 79:999–1006. https://doi.org/10.1136/annrheumdis-2020-217960
doi: 10.1136/annrheumdis-2020-217960
pubmed: 32527868
pmcid: 7299653
Verdoni L, Mazza A, Gervasoni A et al (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395:1771–1778. https://doi.org/10.1016/S0140-6736(20)31103-X
doi: 10.1016/S0140-6736(20)31103-X
pubmed: 32410760
pmcid: 7220177
Belot A, Antona D, Renolleau S, et al (2020) SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Eurosurveillance 25:pii=2001010. https://doi.org/ https://doi.org/10.2807/1560-7917.ES.2020.25.22.2001010
Diorio C, Henrickson SE, Vella LA et al (2020) Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. J Clin Invest 130:5967–5975. https://doi.org/10.1172/JCI140970
doi: 10.1172/JCI140970
pubmed: 32730233
pmcid: 7598044
Speth F, Wellinghausen N, Haas JP (2013) Screening investigations during intensified immunosuppression in children and adolescents. Part 1. Z Rheumatol 72:814–821. https://doi.org/10.1007/s00393-013-1200-3
doi: 10.1007/s00393-013-1200-3
pubmed: 23929241
Speth F, Wellinghausen N, Haas JP (2013) Screening investigations during intensified immunosuppression in children and adolescents. Part 2. Z Rheumatol 72:896–909. https://doi.org/10.1007/s00393-013-1203-0
doi: 10.1007/s00393-013-1203-0
pubmed: 23929242
Gao Y, Chen Y, Liu M et al (2020) Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect 81:e93–e95. https://doi.org/10.1016/j.jinf.2020.05.017
doi: 10.1016/j.jinf.2020.05.017
pubmed: 32502509
pmcid: 7264926
Minotti C, Tirelli F, Barbieri E et al (2020) How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect 81:e61–e66. https://doi.org/10.1016/j.jinf.2020.04.026
doi: 10.1016/j.jinf.2020.04.026
pubmed: 32335173
pmcid: 7179496
Monti S, Balduzzi S, Delvino P et al (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667–668. https://doi.org/10.1136/annrheumdis-2020-217424
doi: 10.1136/annrheumdis-2020-217424
pubmed: 32241793
pmcid: 7211079
Filocamo G, Minoia F, Carbogno S, et al (2020) Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol Apr 25:jrheum.200483. https://doi.org/ https://doi.org/10.3899/jrheum.200483
Michelena X, Borrell H, López-Corbeto M et al (2020) Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 50:564–570. https://doi.org/10.1016/j.semarthrit.2020.05.001
doi: 10.1016/j.semarthrit.2020.05.001
pubmed: 32425260
pmcid: 7229730
Marlais M, Wlodkowski T, Vivarelli M et al (2020) The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Heal 4:e17–e18. https://doi.org/10.1016/S2352-4642(20)30145-0
doi: 10.1016/S2352-4642(20)30145-0
Meyts I, Bucciol G, Quinti I et al (2020) Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2020.09.010
doi: 10.1016/j.jaci.2020.09.010
pubmed: 32980424
pmcid: 7832563
Ferro F, Elefante E, Puxeddu I et al (2020) Editorial: COVID-19: The new challenge for rheumatologists. First update Clin Exp Rheumatol 38:373–382
pubmed: 32452355
Campbell JI, Ocwieja KE, Nakamura MM (2020) A Call for Pediatric COVID-19 Clinical Trials. Pediatrics. https://doi.org/10.1542/peds.2020-1081
doi: 10.1542/peds.2020-1081
pubmed: 33328337
Chen ZM, Fu JF, Shu Q et al (2020) Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr 16:240–246. https://doi.org/10.1007/s12519-020-00345-5
doi: 10.1007/s12519-020-00345-5
pubmed: 32026148
RCPCH Clinical Guidelines (2020) COVID-19 - guidance for paediatric services in management of COVID-19. Last modified on January 11, 2021. https://www.rcpch.ac.uk/resources/covid-19-guidance-paediatric-services . Accessed 30 Jan 2021
Centers for Disease Control and Prevention (2020) COVID-19: Information for Pediatric Healthcare Providers. Last modified on December 30, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html . Accessed 5 Feb 2021
American Academy of Pediatrics (2020) Critical Updates on COVID-19. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/ . Accessed 5 Feb 2020
Calvo C, García López-Hortelano M, de Carlos Vicente JC et al (2020) Recommendations on the clinical management of the COVID-19 infection by the “new coronavirus” SARS-CoV2. Spanish Paediatric Association working group. An Pediatr 92:241.e1-241.e11. https://doi.org/10.1016/j.anpedi.2020.02.001
doi: 10.1016/j.anpedi.2020.02.001
Wahezi DM, Lo MS, Rubinstein TB et al (2020) American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol Art. https://doi.org/10.1002/art.41455
doi: 10.1002/art.41455
Paediatric Rheumatology European Society (2020) Updated PRES recommendations for coronavirus outbreak. Updated on September 21, 2020. https://www.pres.eu/news/newsstory.html?id=29 . Accessed 30 Jan 2021
Gaur PS, Zimba O, Agarwal V, Gupta L (2020) Reporting Survey Based Studies - a Primer for Authors. J Korean Med Sci 35:e398. https://doi.org/10.3346/jkms.2020.35.e398
doi: 10.3346/jkms.2020.35.e398
pubmed: 33230988
pmcid: 7683244
Batu ED, Lamot L, Sag E et al (2020) How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey. Semin Arthritis Rheum 50:1262–1268. https://doi.org/10.1016/j.semarthrit.2020.09.008
doi: 10.1016/j.semarthrit.2020.09.008
pubmed: 33065421
pmcid: 7833192
Batu ED, Özen S (2020) Implications of COVID-19 in pediatric rheumatology. Rheumatol Int 40:1193–1213. https://doi.org/10.1007/s00296-020-04612-6
doi: 10.1007/s00296-020-04612-6
pubmed: 32500409
Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9
doi: 10.1016/S0140-6736(20)31022-9
pubmed: 32423584
pmcid: 7190303
Goldman JD, Lye DCB, Hui DS et al (2020) Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 383:1827–1837. https://doi.org/10.1056/nejmoa2015301
doi: 10.1056/nejmoa2015301
pubmed: 32459919
Grein J, Ohmagari N, Shin D et al (2020) Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 382:2327–2336. https://doi.org/10.1056/nejmoa2007016
doi: 10.1056/nejmoa2007016
pubmed: 32275812
U.S. Food and Drug Administration (2020) COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. Released on August 28, 2020. In: FDA News Release. https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized . Accessed 5 Feb 2021
European Centre for Disease Prevention and Control (2020) Veklury (remdesivir). Date of issue marketing authorisation on July 3, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/veklury . Accessed 5 Feb 2021
Sheahan TP, Sims AC, Leist SR et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222. https://doi.org/10.1038/s41467-019-13940-6
doi: 10.1038/s41467-019-13940-6
pubmed: 31924756
pmcid: 6954302
Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Hear Lung Transplant 39:405–407. https://doi.org/10.1016/j.healun.2020.03.012
doi: 10.1016/j.healun.2020.03.012
Fajgenbaum DC, Khor JS, Gorzewski A et al (2020) Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. Infect Dis Ther 9:435–449. https://doi.org/10.1007/s40121-020-00303-8
doi: 10.1007/s40121-020-00303-8
pubmed: 32462545
The RECOVERY Collaborative Group (2020) Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med July 17:NEJMoa2021436. https://doi.org/ https://doi.org/10.1056/nejmoa2021436
Zhang X, Song K, Tong F et al (2020) First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 4:1307–1310. https://doi.org/10.1182/bloodadvances.2020001907
doi: 10.1182/bloodadvances.2020001907
pubmed: 32243501
pmcid: 7160284
Alzghari SK, Acuña VS (2020) Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review. J Clin Virol 127:104380. https://doi.org/10.1016/j.jcv.2020.104380
doi: 10.1016/j.jcv.2020.104380
pubmed: 32353761
pmcid: 7194791
Ramiro S, Mostard RLM, Magro-Checa C et al (2020) Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: Results of the CHIC study. Ann Rheum Dis 79:1143–1151. https://doi.org/10.1136/annrheumdis-2020-218479
doi: 10.1136/annrheumdis-2020-218479
pubmed: 32719045
pmcid: 7456552
Shakoory B, Carcillo JA, Chatham WW et al (2016) Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial∗. Crit Care Med 44:275–281. https://doi.org/10.1097/CCM.0000000000001402
doi: 10.1097/CCM.0000000000001402
pubmed: 26584195
pmcid: 5378312
Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
doi: 10.1016/j.ijantimicag.2020.105949
pubmed: 32205204
pmcid: 7102549
Singh AK, Singh A, Singh R, Misra A (2020) Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis. Diabetes Metab Syndr Clin Res Rev 14:589–596. https://doi.org/10.1016/j.dsx.2020.05.017
doi: 10.1016/j.dsx.2020.05.017
Tang W, Cao Z, Han M et al (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ 369:m1849. https://doi.org/10.1136/bmj.m1849
doi: 10.1136/bmj.m1849
pubmed: 32409561
pmcid: 7221473
Furtado RHM, Berwanger O, Fonseca HA et al (2020) Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 396:959–967. https://doi.org/10.1016/S0140-6736(20)31862-6
doi: 10.1016/S0140-6736(20)31862-6
pubmed: 32896292
pmcid: 7836431
Juul S, Nielsen EE, Feinberg J et al (2020) Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLOS Med 17:e1003293. https://doi.org/10.1371/journal.pmed.1003293
doi: 10.1371/journal.pmed.1003293
pubmed: 32941437
pmcid: 7498193
Romani S, Gérard A, Fresse A et al (2021) Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. Clin Transl Sci 14:163–169. https://doi.org/10.1111/cts.12883
doi: 10.1111/cts.12883
pubmed: 32964653
Nguyen LS, Dolladille C, Drici MD et al (2020) Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: An analysis of the world health organization pharmacovigilance database. Circulation 142:303–305. https://doi.org/10.1161/CIRCULATIONAHA.120.048238
doi: 10.1161/CIRCULATIONAHA.120.048238
pubmed: 32442023
pmcid: 7365677
Janda A, Schuetz C, Heeg M et al (2020) COVID-19: treatment strategies of German-speaking pediatric rheumatologists: Results of an online survey. Z Rheumatol 79:710–717. https://doi.org/10.1007/s00393-020-00854-8
doi: 10.1007/s00393-020-00854-8
pubmed: 32809050
Zhang Q, Liu Z, Moncada-Velez M et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. https://doi.org/10.1126/science.abd4570
doi: 10.1126/science.abd4570
pubmed: 33335060
pmcid: 7985843
Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. https://doi.org/10.1126/science.abd4585
doi: 10.1126/science.abd4585
pubmed: 32972996
pmcid: 7857407
Bisogno G, Provenzi M, Zama D et al (2020) Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in italian pediatric oncology patients: a study from the infectious diseases working group of the associazione Italiana di Oncologia e Ematologia Pediatrica. J Pediatric Infect Dis Soc 9:530–534. https://doi.org/10.1093/jpids/piaa088
doi: 10.1093/jpids/piaa088
pubmed: 32652521
Landewé RBM, Landewé RBM, MacHado PM et al (2020) EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 79:851–858. https://doi.org/10.1136/annrheumdis-2020-217877
doi: 10.1136/annrheumdis-2020-217877
pubmed: 32503854
Konig MF, Kim AH, Scheetz MH et al (2020) Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis 79:1386–1388. https://doi.org/10.1136/annrheumdis-2020-217690
doi: 10.1136/annrheumdis-2020-217690
pubmed: 32381561
Franzetti M, Pozzetti U, Carugati M et al (2020) Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe coronavirus disease 2019: A case report. Int J Infect Dis 97:215–218. https://doi.org/10.1016/j.ijid.2020.05.050
doi: 10.1016/j.ijid.2020.05.050
pubmed: 32422376
pmcid: 7228890
Welzel T, Samba SD, Klein R et al (2021) COVID-19 in autoinflammatory diseases with immunosuppressive treatment. J Clin Med. https://doi.org/10.3390/jcm10040605
doi: 10.3390/jcm10040605
pubmed: 33562758
pmcid: 7915607
Ortiz-Alvarez O, Morishita K, Avery G et al (2004) Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 31:2501–2506
pubmed: 15570658
Haslak F, Yildiz M, Adrovic A et al (2020) Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int 40:1423–1431. https://doi.org/10.1007/s00296-020-04645-x
doi: 10.1007/s00296-020-04645-x
pubmed: 32661928
Ramirez GA, Gerosa M, Beretta L et al (2020) COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients. Semin Arthritis Rheum 50:1150–1157. https://doi.org/10.1016/j.semarthrit.2020.06.012
doi: 10.1016/j.semarthrit.2020.06.012
pubmed: 32927376
pmcid: 7836639
Hyrich KL, Machado PM (2021) Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol 17:71–72. https://doi.org/10.1038/s41584-020-00562-2
doi: 10.1038/s41584-020-00562-2
pubmed: 33339986